|
Non-Small Cell Lung Carcinoma
|
0.500 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Non-Small Cell Lung Carcinoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer.
|
2569928 |
1989 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Clinical and experimental evidence supports a role for overexpression of the HER2 protooncogene in the progression of human breast, ovarian, and non-small cell lung carcinoma.
|
1679763 |
1991 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
High levels of expression of the c-erbB-2/neu gene have been reported in non-small-cell lung cancer (NSCLC) cell lines and primary tumors from the United States.
|
1350198 |
1992 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
The purpose of this study was to investigate the relationships between chemoresistance and the presence of ras gene point mutations and overexpression of the HER-2/neu gene in NSCLC cell lines, which indicates gene activation.
|
8098377 |
1993 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, information concerning three oncogenes may soon prove to be helpful in the clinical arena: the myc genes in SCLC, and the ras genes and c-erbB-2 in NSCLC.
|
8462246 |
1993 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Using a panel of 20 non-small cell lung cancer (NSCLC) cell lines established from previously untreated patients, we investigated the relationships between intrinsic chemoresistance (to four agents used commonly in the therapy of NSCLC) and HER-2/neu gene expression (which encodes glycoprotein p185neu), p53 gene mutations, and cell proliferation characteristics.
|
8548764 |
1996 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We concluded that sialomucin expression is also a poor indicator of prognosis, which is associated with erbB-2 oncoprotein overexpression, early postoperative recurrence, and cancer death in NSCLC.
|
9105088 |
1997 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
NSCLC cells which overexpress erbB-2 were more resistant to cisplatin-induced cytotoxicity in comparison to cells expressing low levels of erbB-2.
|
9872333 |
1998 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Thus, a prospective analysis of the co-expression of Bcl-2 + HER2 in NSCLC patients may identify patients with a poor prognosis who may benefit from more aggressive therapy.
|
10048471 |
1998 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The growth factor receptor c-erbB-2 is overexpressed in up to 25% of non-small-cell lung cancer (NSCLC) cases.
|
9508209 |
1998 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpression of the growth factor receptor ErbB-2/Her2/Neu has been implicated in the development of non-small-cell lung cancer.
|
10508495 |
1999 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
From the results obtained in this study the following conclusions can be drawn: (a) c-erbB-2 hyperexpressing NSCLC are associated with abnormalities in other biological markers and with a greater rate of relapses; (b) SSCP seemed to be more specific that IHC to detect p53 molecular abnormalities; and (c) the D.I. is the parameter more tightly related with relapse.
|
10481927 |
1999 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Using a FDA-approved standardized diagnostic kit, HercepTest, for detection of HER-2/neu in clinical specimens, we examined the expression of HER-2/neu in NSCLCs in archival paraffin-embedded specimens (N = 81).
|
10928158 |
2000 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
NSCLC cell lines (H460, H358, H322, or H661) were assayed for expression of erbB1 and erbB2, the cell adhesion molecule E-cadherin, secretion of the matrix metalloproteinase 9 (MMP-9), and vascular endothelial cell growth factor (VEGF), as well as their ability to invade Matrigel after 48-hour exposure to 17AAGA.
|
11156083 |
2000 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
|
11236029 |
2000 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that testing 3 molecular markers (c-Ki-ras, p53 and c-erbB-2) improves estimation of prognosis compared to single marker testing and appears to define low (82.6%+/-7.9% 5-year survival) and high risk (40.2%+/-5.5% 5-year survival) groups for treatment failure in potentially curative (RO) resected NSCLC.
|
10945494 |
2000 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer.
|
11153605 |
2000 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The finding that high levels of EGFR showed very little influence on the relationship between p185neu and cisplatin resistance suggests that EGFR may be a less crucial factor in modulating the chemoresistance of NSCLC cells when compared with HER-2/neu.
|
10761709 |
2000 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Testing of molecular marker coexpression (EGFR and HER2-neu) improves the estimation of prognosis and appears to define low- and high-risk groups for treatment failure in curatively resected NSCLC.
|
11448895 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conclude that c-erbB2 is a marker of tumour progression in NSCLC which can be observed on protein level and reflects chromosomal alterations at 17q21.
|
11378338 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
By FACS, we found Her-2/neu overexpression (mean fluorescence intensity >8) in 2 of the 22 non-small cell lung cancer (NSCLC) cell lines (9%), none of 11 small cell lung cancer (SCLC) cell lines, and 4 of 5 breast cancer cell lines.
|
11595720 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Nine specimens (six NSCLC and three SCLC) showed HER-2/neu overexpression.
|
11679181 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Future studies in NSCLC need to include immunohistochemistry and fluorescence in situ hybridization analysis to determine the method of choice for evaluating clinically relevant HER2/neu-positive tumors.
|
11894014 |
2002 |